EUVIMEDEUVIMED entdecken
Crossref

A Tutorial on Improving RCT Power Using Prognostic Score Adjustment for Linear Models

Emilie Højbjerre-Frandsen iD, Mathias Lerbech Jeppesen, Rasmus Kuhr Jensen, Claus Dethlefsen iD, Rasmus Waagepetersen

Pharmaceutical Statistics · 2025

DOI: 10.1002/pst.70028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2025. Verfasst von Emilie Højbjerre-Frandsen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biostatistics, Novo Nordisk A/S, Søborg, Denmark. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Research Design. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Innovationsfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of historical data to increase power in clinical trials has been a topic of interest for many years. A recent approach adjusts linearly for a prognostic score. This is supported by asymptotic optimality results using influence functions for asymptotically linear estimators as well as finite sample optimality results. We review plug‐in and linear estimators of average treatment effect in randomized clinical trials, sample size determination, and linear adjustment for a prognostic score. Guidelines and recommendations for the implementation of linear adjustment for a prognostic score are given including curation of historical data and construction of a prognostic score based on the historical data. A simulation study is conducted to investigate the performance in finite samples, comparing it to standard procedures such as propensity score matching for RCTs (PSM‐RCT) and ANCOVA using simple baseline adjustment. Unlike PSM‐RCT, linear adjustment for a prognostic score avoids biased treatment effect estimates and maintains control of type I error probability. The simulation study shows that the method is robust against deviations from method assumptions and poor performance of the prognostic model. A case study demonstrates an increase in prospective power using linear adjustment with a prognostic score in a phase IIIb clinical trial for type 2 diabetes. A final discussion considers limitations of the method for example in regard to subgroup analysis and the existence of already known prognostic baseline covariates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Randomized Controlled Trials as TopicResearch DesignHumansPrognosisLinear ModelsComputer SimulationSample SizeDiabetes Mellitus, Type 2Clinical Trials, Phase III as Topic

Stichwörter der Autor:innen

causal inferencediabeteshistorical dataprognostic scorerandomized trials

Autor:innen und Institutionen

  • Biostatistics, Novo Nordisk A/S, Søborg, Denmark.
  • Department of Mathematical Sciences, Aalborg University, Aalborg Øst, Denmark.

ORCID-Profile: Emilie Højbjerre-Frandsen, Claus Dethlefsen

Förderung

  • Innovationsfonden

Zitieren

APA

Højbjerre-Frandsen, E., Jeppesen, M. L., Jensen, R. K., Dethlefsen, C., & Waagepetersen, R. (2025). A Tutorial on Improving RCT Power Using Prognostic Score Adjustment for Linear Models. Pharmaceutical Statistics. https://doi.org/10.1002/pst.70028

Vancouver

Højbjerre-Frandsen E, Jeppesen ML, Jensen RK, Dethlefsen C, Waagepetersen R. A Tutorial on Improving RCT Power Using Prognostic Score Adjustment for Linear Models. Pharmaceutical Statistics. 2025. doi:10.1002/pst.70028

BibTeX
@article{HjbjerreFrandsen2025,
  author = {Højbjerre-Frandsen, Emilie and Jeppesen, Mathias Lerbech and Jensen, Rasmus Kuhr and Dethlefsen, Claus and Waagepetersen, Rasmus},
  title = {A Tutorial on Improving RCT Power Using Prognostic Score Adjustment for Linear Models},
  journal = {Pharmaceutical Statistics},
  year = {2025},
  doi = {10.1002/pst.70028}
}
Kostenlos starten →